title: Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.
abstract: Current therapies for Clostridium difficile infection (CDI) are encumbered by treatment failures and recurrences. Due to its high in vitro activity against C. difficile but low activity against the typical intestinal flora, minimal absorption, and durable cure in the hamster model of C. difficile infection, OPT-80 was considered for clinical development as a therapy for CDI. This trial consisted of two phases. Four single oral doses of OPT-80 (100, 200, 300, and 450 mg) were administered in a crossover manner to 16 healthy volunteers in a double-blind, placebo-controlled phase 1A study; a 1- to 2-week washout interval separated the treatments. In the double-blind phase 1B study, 24 healthy subjects were randomized to receive OPT-80 (150, 300, or 450 mg) or placebo for 10 days. In both studies, OPT-80's safety and tolerability were evaluated and the concentrations of OPT-80 and its primary metabolite (OP-1118) in plasma and feces were determined. OPT-80 levels in the urine were also analyzed for the phase 1A study. In both the single-dose and the multiple-dose studies, OPT-80 was well tolerated by all subjects in all dose groups. Maximal plasma concentrations were near or below the limit of quantification (5 ng/ml) across the dose range; urine concentrations were below the detection limit. The fecal total recovery of OPT-80 plus its major metabolite, OP-1118, approximated 100%. The tolerability, high fecal concentration, and low systemic exposure data from these studies support the further clinical development of OPT-80 as an oral therapy for CDI.
authors.affiliation: Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Road, San Diego, CA 92121, USA. ykshue@optimerpharma.com
authors.forename: Y K
authors.initials: YK
authors.lastname: Shue
authors.forename: P S
authors.initials: PS
authors.lastname: Sears
authors.forename: S
authors.initials: S
authors.lastname: Shangle
authors.forename: R B
authors.initials: RB
authors.lastname: Walsh
authors.forename: C
authors.initials: C
authors.lastname: Lee
authors.forename: S L
authors.initials: SL
authors.lastname: Gorbach
authors.forename: F
authors.initials: F
authors.lastname: Okumu
authors.forename: R A
authors.initials: RA
authors.lastname: Preston
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000652:urine; D016360:Clostridioides difficile / Q000187:drug effects; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004761:Enterocolitis, Pseudomembranous / Q000517:prevention & control; D005243:Feces / Q000737:chemistry; D006027:Glycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000652:urine; D064368:Healthy Volunteers; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D006027:Glycosides; C487655:OPT 80